Ponesimod (formerly known as ACT-128800; ACT128800; Ponvory) is an orally bioavailable and selective agonist of sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) approved in 2021 by FDA to treat relapsing forms of multiple sclerosis. It is a new therapeutic approach in lymphocyte-mediated autoimmune diseases.

纯度：≥98%

CAS：854107-55-4